-
Published 9/22/2025
Degirmenci HB, Peloquin CE, Westerland M, Lodi S, Machado PM, Jafarzadeh SR, Neogi T, Gensler LS, Dubreuil M, Liew JW. Trends in Opioid Prescriptions in Individuals with Axial Spondyloarthritis in the US and UK in the Last Two Decades: Analysis of Electronic Health Records and Insurance Claims Data. Arthritis Care Res (Hoboken). 2025 Sep 22. PMID: 40977482.
-
Published 9/11/2025
Achkar A, Peloquin C, Liew JW, Dubreuil M. Targeted and biologic therapies and risk of total knee or hip replacement in axial spondyloarthritis and psoriatic arthritis. Clin Rheumatol. 2025 Sep 11. PMID: 40936006.
-
Published 9/1/2025
Dubreuil M, Walsh JA, Deodhar A, Gensler LS, Curtis JR, Welby S, Pilipczuk O, Beaty S, Mørup MF, Taieb V, Anjohrin S. Real-World Use of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Axial Spondyloarthritis in the United States: Persistence, Variables Associated With Persistence, and Dosing Variations. Pharmacoepidemiol Drug Saf. 2025 Sep; 34(9):e70197. PMID: 40854555.
-
Published 8/29/2025
Dubreuil M, Magrey M, Haeffs K, Ivanov E, Gandrup Horan J. Patient Diagnostic Journey and Time to Diagnosis in Axial Spondyloarthritis: A Retrospective Cohort Study Using US Claims Data. Rheumatol Ther. 2025 Oct; 12(5):991-1006. PMID: 40879862.
-
Published 6/1/2025
Sendaydiego X, Gold LS, Dubreuil M, Andrews JS, Reid P, Liew DFL, Goulabchand R, Hughes GC, Sparks JA, Jarvik JG, Singh S, Liew JW, Singh N. Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis. Rheumatology (Oxford). 2025 Jun 01; 64(6):3434-3443. PMID: 39936579.